What question did this study set out to answer?

To assess the efficacy and safety of mepolizumab compared with placebo for achieving and sustaining remission in patients with eosinophilic granulomatosis with polyangiitis.

May 17, 2017New England Journal of MedicineOpen Access

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

View Full Paper

Ask AI

Bookmark

Authors

MWMichael E. WechslerNational Jewish Health PAPraveen AkuthotaUniversity of San Diego DJDavid JayneKarunya University

Discussion

Member takes

Implication

Randomized trial reveals mepolizumab increases remission and lowers steroid use in eosinophilic granulomatosis with polyangiitis, suggesting targeted therapy benefits despite partial response.

Key Points

To assess the efficacy and safety of mepolizumab compared with placebo for achieving and sustaining remission in patients with eosinophilic granulomatosis with polyangiitis.
Randomized, placebo-controlled trial evaluating mepolizumab against placebo in participants with eosinophilic granulomatosis with polyangiitis (ClinicalTrials.gov number, NCT02020889).
Assessed weeks in remission, the proportion of participants achieving protocol-defined remission, and the ability to taper glucocorticoid dosages.
Mepolizumab resulted in significantly more weeks in remission and a higher proportion of participants in remission than placebo, enabling reduced glucocorticoid use.
Approximately half of the participants treated with mepolizumab achieved protocol-defined remission.

Cite This Study

Wechsler et al. (2017) studied this question.

synapsesocial.com/papers/69d7914bf44a16d01ef31b25 https://doi.org/10.1056/nejmoa1702079

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals mepolizumab increases remission and lowers steroid use in eosinophilic granulomatosis with polyangiitis, suggesting targeted therapy benefits despite partial response.

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

Discussion

Member takes

Implication

Key Points

Cite This Study

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider